(Boursier.com) — BOYDSense SAS, a subsidiary of Alpha MOS, was chosen in December 2021 by the EIC as part of its Horizon Europe funding program (2021-2027), co-managed with the European Commission (EC).
Obtaining the first part of this non-dilutive financing of 2.5 ME now allows BOYDSense to cross several key stages in the development and industrialization of its non-invasive product. First, the recruitment of engineers and scientists for the ‘R&D’ department in Toulouse, then the acceleration of clinical trials in Europe to rapidly validate the device. The EIC’s assistance will also enable the company to obtain ISO 13485 certification, a necessary step to comply with international medical device regulations.
Finally, more prototypes will be produced: the clinical trials conducted in parallel will thus make it possible to obtain clinical evidence more quickly.
“This grant will help us generate more clinical trial data and therefore improve our algorithms. This is a big step for BOYDSense and patients with diabetes as blood glucose monitoring by injection may soon be replaced by measurements. non-invasive,” said Ben Delhey, CEO of BOYDSense.
©2022 Boursier.com